Frontotemporal lobar degeneration

M Grossman, WW Seeley, AL Boxer, AE Hillis… - Nature Reviews …, 2023 - nature.com
Frontotemporal lobar degeneration (FTLD) is one of the most common causes of early-onset
dementia and presents with early social–emotional–behavioural and/or language changes …

CNS-derived blood exosomes as a promising source of biomarkers: opportunities and challenges

S Hornung, S Dutta, G Bitan - Frontiers in Molecular Neuroscience, 2020 - frontiersin.org
Eukaryotic cells release different types of extracellular vesicles (EVs) including exosomes,
ectosomes, and microvesicles. Exosomes are nanovesicles, 30–200 nm in diameter, that …

Neurofilament light chain as biomarker for amyotrophic lateral sclerosis and frontotemporal dementia

F Verde, M Otto, V Silani - Frontiers in neuroscience, 2021 - frontiersin.org
Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are two related
currently incurable neurodegenerative diseases. ALS is characterized by degeneration of …

Frontotemporal dementia, where do we stand? A narrative review

A Antonioni, EM Raho, P Lopriore, AP Pace… - International journal of …, 2023 - mdpi.com
Frontotemporal dementia (FTD) is a neurodegenerative disease of growing interest, since it
accounts for up to 10% of middle-age-onset dementias and entails a social, economic, and …

[HTML][HTML] The diagnostic performance of neurofilament light chain in CSF and blood for Alzheimer's disease, frontotemporal dementia, and amyotrophic lateral sclerosis …

LM Forgrave, M Ma, JR Best, ML DeMarco - Alzheimer's & Dementia …, 2019 - Elsevier
Introduction A systematic review and meta-analysis was performed regarding the diagnostic
performance of neurofilament light chain (NfL) in CSF and blood. Methods A database …

Cerebrospinal fluid biomarkers in autopsy-confirmed Alzheimer disease and frontotemporal lobar degeneration

N Mattsson-Carlgren, LT Grinberg, A Boxer… - Neurology, 2022 - AAN Enterprises
Background and Objectives To determine how fully automated Elecsys CSF immunoassays
for β-amyloid (Aβ) and tau biomarkers and an ultrasensitive Simoa assay for neurofilament …

Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study

EL van der Ende, LH Meeter, JM Poos… - The Lancet …, 2019 - thelancet.com
Summary Background Neurofilament light chain (NfL) is a promising blood biomarker in
genetic frontotemporal dementia, with elevated concentrations in symptomatic carriers of …

Fluid biomarkers in frontotemporal dementia: past, present and future

IJ Swift, A Sogorb-Esteve, C Heller… - Journal of Neurology …, 2021 - jnnp.bmj.com
The frontotemporal dementia (FTD) spectrum of neurodegenerative disorders includes a
heterogeneous group of conditions. However, following on from a series of important …

Serum neurofilament light chain in behavioral variant frontotemporal dementia

P Steinacker, S Anderl-Straub, J Diehl-Schmid… - Neurology, 2018 - AAN Enterprises
Objective To determine the association of serum neurofilament light chain (NfL) with
functional deterioration and brain atrophy during follow-up of patients with behavioral variant …

Neurofilament light chain protein in neurodegenerative dementia: a systematic review and network meta-analysis

Y Zhao, Y Xin, S Meng, Z He, W Hu - Neuroscience & Biobehavioral …, 2019 - Elsevier
The diagnostic value of neurofilament light chain protein in neurodegenerative dementia
diseases is still controversial. A systematic literature search was performed to identify …